1-苯乙基-4-苯基-4-哌啶基乙酸酯 | 64-52-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-苯乙基-4-苯基-4-哌啶基乙酸酯
• 英文名称: acetic acid-(1-phenethyl-4-phenyl-[4]piperidyl ester)
• 英文别名: Essigsaeure-(1-phenaethyl-4-phenyl-[4]piperidylester)；1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine；[4-phenyl-1-(2-phenylethyl)piperidin-4-yl] acetate
• CAS: 64-52-8
• 化学式: C₂₁H₂₅NO₂
• 分子量: 323.435
• InChiKey: BVURVTVDNWSNFN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  1-苯乙基-4-苯基-4-哌啶醇	1-phenethyl-4-phenyl-piperidin-4-ol	94913-96-9	C19H23NO	281.398

反应信息

• 作为产物：
  描述：

  N-(2-苯乙基)-4-哌啶酮 在 吡啶 、 乙醚 作用下， 生成 1-苯乙基-4-苯基-4-哌啶基乙酸酯
  参考文献：
  名称：

  Beckett et al., Journal of medicinal and pharmaceutical chemistry, 1959, vol. 1, p. 37,54

  摘要：

  DOI：

文献信息

• Methods and compositions for the treatment of heart failure and other disorders
  申请人：Ironwood Pharmaceuticals, Inc.

  公开号：EP2650303A1

  公开（公告）日：2013-10-16

  Peptides that act as GC-C receptor agonists and contain at least one D-Cys and are useful for the treatment of diuresis and heart disease as well as other disorders are described.

  本文介绍了作为 GC-C 受体激动剂并含有至少一种 D-Cys 的多肽，这些多肽可用于治疗利尿和心脏病以及其他疾病。
• Controlled release formulation with continuous efficacy
  申请人：Egalet Ltd.

  公开号：EP2700400A1

  公开（公告）日：2014-02-26

  The present invention relates to pharmaceutical compositions, which provide controlled release of a drug. The compositions are suitable for continuous administration as they remain effective throughout the treatment regimen. The present invention also relates to the use of the compositions for preparation of a medicament for continuous treatment of an individual.

  本发明涉及可控制药物释放的药物组合物。这些组合物适合连续给药，因为它们在整个治疗过程中都能保持有效。本发明还涉及使用这些组合物制备用于对个人进行连续治疗的药物。
• METHODS OF NORMALISING MEASURED OXYCODONE CONCENTRATIONS AND TESTING FOR NON-COMPLIANCE WITH A TREATMENT REGIMEN
  申请人：Ameritox Limited Partnership

  公开号：EP2942055A1

  公开（公告）日：2015-11-11

  Methods for monitoring subject compliance with a prescribed treatment regimen are disclosed. In one embodiment, the method comprises measuring a drug level in fluid of a subject and normalizing said measured drug level as a function of one or more parameters associated with the subject. The normalized drug level is compared to a reference value and associated confidence intervals or to a concentration range. The reference value and associated confidence intervals and/or the concentration range may be normalized based on one or more parameters associated with subjects in a reference population.

  本发明公开了用于监测受试者是否遵从处方治疗方案的方法。在一个实施方案中，该方法包括测量受试者体液中的药物浓度，并将所测得的药物浓度归一化为与受试者相关的一个或多个参数的函数。将归一化后的药物浓度与参考值及相关置信区间或浓度范围进行比较。参考值和相关置信区间和/或浓度范围可根据参考人群中与受试者相关的一个或多个参数进行归一化。
• PHARMACEUTICAL COMPOSITION PROVIDED WITH ABUSE-PREVENTION FUNCTION
  申请人：Daiichi Sankyo Co., Ltd.

  公开号：EP3175845A1

  公开（公告）日：2017-06-07

  An object of the present invention is to provide a pharmaceutical composition having abuse deterrent properties and thereby prevent the abuse of a pharmacologically active component by an abuser (abuse through snorting, abuse through injection, or abuse through snorting or injection of a temporarily extracted drug). The present invention provides a pharmaceutical composition having abuse deterrent properties that possesses both a physical barrier and a chemical barrier to being abused by an abuser, a method for producing the same and a method for using the same.

  本发明的目的是提供一种具有阻止滥用特性的药物组合物，从而防止药理活性成分被滥用者滥用（通过吸食滥用、通过注射滥用或通过吸食或注射临时提取的药物滥用）。本发明提供了一种具有阻止滥用特性的药物组合物，这种组合物具有物理屏障和化学屏障，可防止滥用者滥用，还提供了一种生产这种组合物的方法和一种使用这种组合物的方法。
• Pharmaceutical compositions resistant to abuse
  申请人：Egalet Ltd.

  公开号：US10105321B2

  公开（公告）日：2018-10-23

  The present invention provides immediate release pharmaceutical compositions for oral administration that are resistant to abuse.

  本发明提供了抗滥用的口服速释药物组合物。